NCT03017131View on ClinicalTrials.gov

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 8, 2017

Primary Completion Date

March 23, 2020

Study Completion Date

March 23, 2032

Conditions
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Interventions
BIOLOGICAL

Aldesleukin

Given SC

DRUG

Cyclophosphamide

Given IV

DRUG

Decitabine

Given IV

BIOLOGICAL

Genetically Engineered NY-ESO-1-specific T Lymphocytes

Given IV and IP

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Roswell Park Cancer Institute

OTHER